Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in AMKL and Myelofibrosis
NCT02530619Phase 1Unknown
- Sponsor
- Northwestern University
- Start
- Oct 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in acute megakaryoblastic leukemia (AMKL) and myelofibrosis (MF), sponsored by Northwestern University. Primary endpoint: Safety Profile of Alisertib Per NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Status: unknown.
02
Drugs
alisertib
03
Conditions
acute megakaryoblastic leukemia (AMKL)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02530619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530619.